Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy

BACKGROUND: Circulating tumor DNA (ctDNA) has been proven to be a promising tumor-specific biomarker in solid tumors, but its clinical utility in risk stratification and early prediction of relapse for diffuse large B cell lymphoma (DLBCL) has not been well explored. METHODS: Here, using a lymphoma-...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Miaomiao, Mi, Lan, Wang, Chunyang, Wang, Xiaojuan, Zhu, Jianhua, Qi, Fei, Yu, Hui, Ye, Yingying, Wang, Dedao, Cao, Jiaowu, Hu, Dingyao, Yang, Quanyu, Zhao, Dandan, Ma, Tonghui, Song, Yuqin, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594942/
https://www.ncbi.nlm.nih.gov/pubmed/36280874
http://dx.doi.org/10.1186/s12916-022-02562-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594942/
https://www.ncbi.nlm.nih.gov/pubmed/36280874
http://dx.doi.org/10.1186/s12916-022-02562-3

Ejemplares similares